Small Molecules News and Research

RSS

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

The hopes of many that ALS (commonly referred to as Lou Gehrig's disease) will one day be a disease of the past, studied in medical textbooks, conquered by the dedication of those who have worked tirelessly to eradicate it might be realized in our lifetime.

6 Dec 2004

Cellular enzyme represents a potential new target for developing improved HIV drugs

Scientists have discovered that a cellular enzyme helps ferry HIV genetic instructions out of the cell nucleus where they can then be translated into proteins to begin their most destructive work.

1 Nov 2004

Trojan horse technique offers potential new therapeutic approach to Alzheimer's disease

A potential new therapeutic approach to Alzheimer's disease protects brain cells in culture by drastically reducing the neurotoxic amyloid protein aggregates that are critical to the development of the disease.

29 Oct 2004

Patent pending discovery could help type 2 diabetics

Scientists from MitoChroma Research have recently announced a patent-pending discovery that could complement current medical management modalities for Type 2 Diabetes, insulin resistance and the set of related conditions called "Metabolic Syndrome."

4 Oct 2004

Researchers have successfully targeted an HIV protein that has eluded existing therapies

Researchers targeted Nef, a protein responsible for accelerating the development of acquired immunodeficiency syndrome, or AIDS. Nef was targeted with small molecules synthesized by the researchers – molecules that disrupted Nef’s interaction with other proteins.

26 Sep 2004

Drug combo may have a greater impact on cancer development

Cancer researchers have long suggested that new targeted drugs may work best when paired with other therapies. In a new study published today in Cancer Research, scientists have taken some of the first steps to demonstrate this synergy in mouse and cell line models.

16 Sep 2004

Liver cancer genes cluster into two subsets that correlate to survival

An analysis of the gene expression patterns of 91 unrelated liver tumors revealed two distinctive subclasses highly associated with patient survival, according to a new study published in the September 2004 issue of Hepatology.

14 Sep 2004

Scientists have uncovered a key driver behind the progression of prostate cancer

Scientists at Fred Hutchinson Cancer Research Center have uncovered a key driver behind the progression of prostate cancer, a discovery that the researchers believe could spawn new treatments to prevent the cancer's spread and extend survival.

23 Aug 2004

Small molecules as artificial gene regulators

Scientists have been trying for some time to develop molecules that mimic natural regulators of gene expression.

22 Aug 2004

Existing hepatitis drug could lead to the development of new drugs for the treatment of anthrax

Thanks to new screening tools, and some luck, researchers at the University of Chicago have discovered three unrelated compounds that inhibit the two toxins – edema factor and lethal factor -- that have made anthrax one of the most feared of potential bioterror agents.

21 Aug 2004

Large-scale computer simulations help understand SARS

A Mayo Clinic researcher is the first to develop a series of three-dimensional (3D) models of an enzyme responsible for the replication of the deadly SARS (Severe Acute Respiratory syndrome) virus.

17 Aug 2004

New service-oriented laboratory focused on bioanalysis and pharmacokinetics

Oregon Health & Science University researchers will more quickly move benchtop discoveries toward drug discoveries with the help of a new, service-oriented laboratory focused on bioanalysis and pharmacokinetics.

11 Aug 2004

Cyntellect issued patent covering LaserFect(TM) technology

Cyntellect a privately-held biotechnology company, has announced the issuance of U.S. Patent No. 6,753,161 covering the Company's LaserFect(TM) technology.

6 Aug 2004

The p53 transcription factor plays a vital role in preventing cancer onset

Researchers at the Uppsala Branch of the Ludwig Institute for Cancer Research have discovered that the transcription factor Yin Yang 1 (YY1) is a novel regulator of the tumor suppressor p53, which is inactivated in at least half of all human cancers.

2 Aug 2004

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

New leads for the discovery of anthrax antitoxins that could be used in conjunction with antibiotics to treat late-stage anthrax

A team of researchers led by The Burnham Institute’s Robert C. Liddington has determined the crystal structure of the binding complex between anthrax toxin and one of its host receptors.

8 Jul 2004

Continued commercial development of research into DNA repair

Recent developments have greatly improved the understanding of the mechanisms used by cells to identify and repair breaks in DNA, and the potential for drugs that target DNA repair in the treatment of a range of human diseases including cancer.

28 Jun 2004

Biocompatibility of interactions that occur between implanted biomaterials and the host living tissue

Researchers across the world are working toward biocompatibility by optimizing interactions that occur between implanted biomaterials and the host living tissue.

21 Jun 2004

Research on the potential oral delivery of a current intravenous cancer drug using polymeric nano-delivery systems technology

Labopharm Inc. today announced that it has entered into an agreement with Debiopharm S.A. under which Debiopharm has engaged Labopharm to conduct research on the potential oral delivery of a current intravenous cancer drug using Labopharm’s proprietary polymeric nano-delivery systems technology (also referred to as micelles technology).

16 Jun 2004

Novel molecular targeting technologies to deliver gene-silencing therapy

Researchers have combined novel molecular targeting technologies to deliver gene-silencing therapy specifically to tumor cells shielded by a normally impermeable obstacle, the blood brain barrier.

1 Jun 2004